SOURCE: Marina Biotech, Inc.

Marina Biotech, Inc.

November 24, 2010 16:10 ET

Marina Biotech, Inc. to Present at 22nd Annual Piper Jaffray Health Care Conference

BOTHELL, WA--(Marketwire - November 24, 2010) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that it will present at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1, 2010, at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time) at the New York Palace Hotel in New York City. J. Michael French, Marina Biotech President and Chief Executive Officer, will participate in a "fireside" chat with Ted Tenthoff, Managing Director and Senior Research Analyst at Piper Jaffray. 

A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company's website at Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one and a half hours after the live presentation and will be archived for three months.

About Marina Biotech, Inc.

Marina Biotech (formerly known as MDRNA, Inc.) is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at

Contact Information

  • Contact:
    Marina Biotech, Inc.:
    Pete Garcia
    Chief Financial Officer
    (425) 908-3603